APA (7th ed.) Citation

Di Zeo‐Sánchez, D. E., Díaz‐Alberola, I., Pinazo‐Bandera, J. M., García‐Cortés, M., Sanabria‐Cabrera, J., Robles‐Díaz, M., . . . Stephens, C. (2025). Intestinal permeability and immune‐inflammatory markers in patients with idiosyncratic drug‐induced liver injury, drug‐induced steatosis and metabolic dysfunction–associated steatotic liver disease (MASLD). British Journal of Pharmacology, 182(21), 5303. https://doi.org/10.1111/bph.70123

Chicago Style (17th ed.) Citation

Di Zeo‐Sánchez, Daniel E., et al. "Intestinal Permeability and Immune‐inflammatory Markers in Patients with Idiosyncratic Drug‐induced Liver Injury, Drug‐induced Steatosis and Metabolic Dysfunction–associated Steatotic Liver Disease (MASLD)." British Journal of Pharmacology 182, no. 21 (2025): 5303. https://doi.org/10.1111/bph.70123.

MLA (9th ed.) Citation

Di Zeo‐Sánchez, Daniel E., et al. "Intestinal Permeability and Immune‐inflammatory Markers in Patients with Idiosyncratic Drug‐induced Liver Injury, Drug‐induced Steatosis and Metabolic Dysfunction–associated Steatotic Liver Disease (MASLD)." British Journal of Pharmacology, vol. 182, no. 21, 2025, p. 5303, https://doi.org/10.1111/bph.70123.